Risk and benefit of CD133+ progenitors.
Ascione
Raimondo
R
Madeddu
Paolo
P
D000071916:AC133 Antigen; D053687:Adult Stem Cells / Q000276:immunology / Q000637:transplantation*; D000818:Animals; D015703:Antigens, CD / Q000032:analysis*; D017719:Diabetic Foot / Q000503:physiopathology / Q000601:surgery; D053686:Fetal Stem Cells / Q000276:immunology / Q000637:transplantation*; D006023:Glycoproteins / Q000032:analysis*; D006801:Humans; D009203:Myocardial Infarction / Q000503:physiopathology / Q000601:surgery; D009369:Neoplasms / Q000209:etiology; D010455:Peptides / Q000032:analysis*; D018570:Risk Assessment; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D016896:Treatment Outcome; D014945:Wound Healing
D000071916:AC133 Antigen; D015703:Antigens, CD; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides